CBP/p300 bromodomain: new promising epigenetic target
Visualized Cancer Medicine · 2022
DOI: 10.1051/vcm/2022004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Visualized Cancer Medicine, 2022. Verfasst von Qiuping Xiang und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
CREB (cAMP responsive element binding protein) binding protein (CBP) and adenovirus E1A-associated 300 kDa protein (p300) are histone acetyltransferases, which are necessary for multiple cellular processes. Thus, CBP/p300 are promising potential antitumor targets. To date, despite various small molecule inhibitors of CBP/p300 bromodomain (BRD) having been reported, no specific inhibitor was approved by U.S. Food and Drug Administration (FDA). In this review, we described the discovery, optimization, binding mode evaluation, selectivity and potency evaluation, and therapeutic opportunities of our CBP/p300 bromodomain inhibitors, aiming to inspire new inhibitor design and advance drug discovery research in this field. One video presents the development of CBP/p300 bromodomain inhibitors.
Zitieren
APA
Xiang, Q., Zhou, Y., Zhang, Y., & Xu, Y. (2022). CBP/p300 bromodomain: new promising epigenetic target. Visualized Cancer Medicine. https://doi.org/10.1051/vcm/2022004
Vancouver
Xiang Q, Zhou Y, Zhang Y, Xu Y. CBP/p300 bromodomain: new promising epigenetic target. Visualized Cancer Medicine. 2022. doi:10.1051/vcm/2022004
BibTeX
@article{Xiang2022,
author = {Xiang, Qiuping and Zhou, Yang and Zhang, Yan and Xu, Yong},
title = {CBP/p300 bromodomain: new promising epigenetic target},
journal = {Visualized Cancer Medicine},
year = {2022},
doi = {10.1051/vcm/2022004}
}
EUVIMED